This published Meta-Analysis by Lin is an indirect comparison between two drugs Chiglitazar and Thiazolidinedione which are commonly used for glycemic control in type-II diabetes mellitus. In terms of safety and efficacy, this Meta-Analysis is inconclusive.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10999034 | PMC |
| http://dx.doi.org/10.4239/wjd.v15.i3.565 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chiglitazar ameliorates dehydroepiandrosterone-induced polycystic ovary syndrome in rats.
J Ovarian Res
November 2024
Department of Endocrinology, Chongqing University Three Gorges Hospital, Chongqing, 404000, China.
Background: Polycystic ovary syndrome (PCOS) is an endocrine and metabolic disorder accompanied by ovulatory dysfunction. Insulin resistance (IR) is a key pathogenic mechanism in PCOS, and insulin sensitizers, such as metformin and pioglitazone, can improve PCOS symptoms. Chiglitazar, a pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist, is also an insulin sensitizer; however, its therapeutic effects have not yet been studied in PCOS.
View Article and Find Full Text PDFChiglitazar and Thiazolidinedione in patients with type 2 diabetes: Which is better?
World J Diabetes
March 2024
Department of Ophthalmology, All India Institute of Medical Sciences, Hyderabad 508126, Telangana, India.
This published Meta-Analysis by Lin is an indirect comparison between two drugs Chiglitazar and Thiazolidinedione which are commonly used for glycemic control in type-II diabetes mellitus. In terms of safety and efficacy, this Meta-Analysis is inconclusive.
View Article and Find Full Text PDFIndirect comparison of efficacy and safety of chiglitazar and thiazolidinedione in patients with type 2 diabetes: A meta-analysis.
World J Diabetes
October 2023
Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing 100044, China.
Background: Chiglitazar is an emerging pan-agonist of all peroxisome proliferator activated receptors (PPAR)-α, δ and γ, and has therapeutic potential for type 2 diabetes (T2D). However, to date, no clinical studies or meta-analyses have compared the efficacy and safety of chiglitazar and traditional PPAR-γ agonist thiazolidinediones (TZDs). A meta-analysis concerning this topic is therefore required.
View Article and Find Full Text PDFPharmacokinetic Interaction of Chiglitazar with CYP3A4 Inducer or Inhibitor: An Open-Label, Sequential Crossover, Self-Control, 3-Period Study in Healthy Chinese Volunteers.
Clin Pharmacol Drug Dev
February 2023
Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, China.
Chiglitazar, a pan agonist of non-thiazolidinedione peroxisome proliferator-activated receptor, has the potential to regulate blood sugar, improve lipid metabolism, and reduce cardiovascular complications. This study aimed to examine the effect of cytochrome P450 (CYP) 3A4 inhibitors/inducers on the in vivo metabolism of chiglitazar and provide a reference for the clinical combination use of chiglitazar. A single-center, open-label, sequential crossover, and self-control study was carried out in 24 healthy subjects to determine the pharmacokinetics of chiglitazar dosed with and without CYP3A4 inhibitors and inducers.
View Article and Find Full Text PDFChiglitazar: First Approval.
Drugs
January 2022
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Chiglitazar (Bilessglu) is an orally administered, non-thiazolidinedione small-molecule agonist of α, δ and γ peroxisome proliferator-activated receptors (PPARs) being developed by Chipscreen Biosciences for the treatment of type 2 diabetes (T2D) and non-alcoholic steatohepatitis. In October 2021, chiglitazar was approved in China for use as an adjunct to diet and exercise to improve glycaemic control in adult patients with T2D. The drug is also in phase 2 clinical development in China for the treatment of non-alcoholic steatohepatitis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!